

The screenshot shows a web browser window with the URL <http://www.symlinrems.com>. The page header includes the SymlinPen logo (pramlintide acetate pen-injector) and navigation links for Prescribing Information and Medication Guide. A disclaimer states, "This site is for U.S. Health Care Providers only." A "Bookmark This Page" button is also present.

The main content area is titled "FDA Required SYMLIN REMS Safety Information". It features a yellow header for "SYMLIN REMS Purpose" and a blue header for "Risk Evaluation and Mitigation Strategy (REMS)".

SYMLIN REMS Purpose

The purpose of the SYMLIN REMS program is to inform health care providers about the following serious risks of SYMLIN:

- Increased risk of severe hypoglycemia, particularly in patients with type 1 diabetes.
- Importance of insulin dose reduction

Counsel and instruct your patients on insulin dose reduction to minimize the risk of hypoglycemia.

- Proper patient selection.** SYMLIN is **contraindicated** in patients with any of the following:
 - Hypoglycemia unawareness
 - Confirmed gastroparesis
 - Serious hypersensitivity to SYMLIN or any of its product components

Please see the non-promotional [SYMLIN Factsheet](#), reviewed by the FDA for more detailed safety information.

Risk Evaluation and Mitigation Strategy (REMS)

A REMS is a strategy to manage known or potential serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) to ensure that the benefits of a drug outweigh its risks. The FDA has required a REMS for SYMLIN.

SYMLIN and SymlinPen are registered trademarks of the AstraZeneca group of companies.

Navigation links: [Prescribing Information](#) | [Medication Guide](#) | [REMS](#)

AstraZeneca logo

REMS Materials

- [REMS Factsheet](#)
- [REMS Letter for Health Care Provider \(print version\)](#)
- [REMS Letter for Professional Societies \(print version\)](#)

BROWSER PAGE TITLE:
SYMLIN REMS page

PROGRAMMING NOTES:
1) AstraZeneca will include a prominent link on the SYMLIN HCP homepage for REMS materials. The link will direct HCPs to this separate webpage (<http://www.SYMLINREMS.com>).

2) This REMS website is independent of link to the promotional and/or commercial website and non-REMS materials about the product.

3) The REMS website will be accessible directly through a search engine.